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Abstract
Background: Remifentanil and dexmedetomidine are common agents used in general anaesthesia, monitored anaesthesia care and critical 
care. When combined with inhaled or intravenous anaesthetic agents intra-operatively, they provide analgesia, lower general anaesthetic 
requirements and provide sedation and analgesia in the peri-operative period if  indicated. Pharmacodynamically, they cause hypotension 
and bradycardia which are reversible if  well managed. Past studies of  these drugs have shown a significant proportion of  patients with 
hypotension when compared with similar agents or in isolation. This study compares these two drugs on the effect of  hypotension when 
used as adjuncts to general anaesthesia at low dose standard rate of  infusions.  
Objective: To compare the proportion of  hypotension episodes in a group of  adult patients receiving dexmedetomidine infusion at 
0.4mcg/kg/hr versus a group receiving remifentanil infusion at 0.2mcg/kg/min, severity of  hypotension and physician interventions in 
each group. 
Methods: One hundred and four patients scheduled for elective surgery under general anaesthesia were randomized into two groups:
Control group; received remifentanil infusion at 0.2mcg/kg/min
Intervention group; received dexmedetomidine at 0.4mcg/kg/hr.
General anaesthesia was standardized in both groups. The patients were blinded to the study. Baseline blood pressures of  all patients were 
determined prior to induction. The patient’s demographic characteristics were recorded. The number of  patients who developed hypoten-
sion, the frequency of  hypotension and the physician interventions were recorded and analysed.  
Results: The age and gender characteristics were different between the two groups (p values <0.023 and 0.05 respectively) however they 
did not affect the proportion of  patients with hypotension. The weight, baseline pressures and ASA status of  the patients within the 
groups were similar. The operative procedures varied within the groups. General surgery did not influence the outcome of  hypotension in 
both arms.  The duration of  surgery in remifentanil group exceeded that of  Dexmedetomidine p value<0.0005 however the time to the 
first episode of  hypotension was similar between the groups. The episodes of  hypotension were fewer in the dexmedetomidine arm and 
the proportion of  patients with hypotension were higher in the remifentanil arm, p value<0.001, R.R 0. = 0.5938, 95% C.I=   0.329-0.819 
The physician interventions administered were similar between the two groups except the use of  ephedrine between the groups.  
Conclusion: Among this population, at standard infusion rates, the proportion of  patients that risk hypotension was greater in those 
undergoing elective surgery receiving remifentanil at 0.2mcg/kg/min than in dexmedetomidine at 0.4mcg/kg/hr under isoflurane based 
anaesthesia. 
Keywords:  Risk of  hypotension, remifentanil versus dexmedetomidine infusions, general anaesthesia, Aga Khan University Hospital, 
Nairobi.
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Introduction  
Balanced anaesthesia is a triad of  hypnosis/amnesia, an-
algesia and muscle relaxation. An ideal anaesthetic agent 
would be one drug that provides all three which is cur-
rently unavailable. With the exception of  ketamine and 
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dexmedetomidine which have analgesic properties, in-
haled volatile and intravenous anaesthetic agents have 
only amnestic/hypnotic properties1,2.  
  
Balanced anaesthesia is provided by the use of  hypnotic 
agents which could be intravenous or a volatile anaesthet-
ic agent for example propofol and isoflurane, a muscle 
relaxant which may be used to provide intra-operative pa-
ralysis to skeletal muscle and analgesic agents to control 
pain and add the effect of  sedation to the anaesthesia.  
     
Short acting opioids such as remifentanil, fentanyl, alfen-
tanil and sufentanil have been used intra-operatively as 
infusions for pain control and are combined with volatile 
inhalational agents or intravenous agents to provide gen-
eral anaesthesia3. Remifentanil is the most common opi-
oid used as an infusion intra-operatively at our hospital. It 
is associated with deep analgesia, has a fast recovery and 
deemed useful for patients who have a risk of  intra-oper-
ative awareness, obstructive sleep apnoea and for patients 
who require early ambulation post-operatively4.  
Remifentanil can be used as an adjunct with volatile an-
aesthetics and total intravenous anaesthesia with hypnotic 
agents5,6. At the appropriate doses, it can facilitate endo-
tracheal intubation without muscle relaxant5. Remifent-
anil when used intra-operatively causes chest wall rigidity, 
hypotension and bradycardia, post-operatively with opi-
oid induced tolerance or hyperalgesia, pruritus, nausea 
and vomiting which prolong recovery from general an-
aesthesia and surgery4,5.   
  
Dexmedetomidine is a classical anaesthetic agent that 
has been gaining popularity since the early 1990’s. It is 
an alpha 2 selective agonist which provides sedation and 
analgesia.
Dexmedetomidine is also used in general anaesthesia 
in various surgeries including major specialties such as 
cardiothoracic surgery and neurosurgery7. Dexmedeto-
midine has been used as analgesia post-operatively as an 
infusion for major cardiothoracic surgeries8,9. It has been 
shown to reduce intra-operative analgesic consumption 
and post-operative induced opioid hyperalgesia by acting 
centrally in the brain and spinal cord9,10,11,12,13,14.  
Intra-operatively, dexmedetomidine reduces the MAC of  
inhaled anaesthetic agents as demonstrated by Wong et al 
and has been used in combination with propofol as total 
intravenous anaesthesia and patients did not portray any 
overt signs of  intra-operative awareness10,15,16.  
Dexmedetomidine and remifentanil are two different 
drugs that have a common effect of  analgesia, sedation, 
hypotension and bradycardia. Bradycardia is treated with 
an anti-cholinergic agent. Hypotension is reduced/ treat-
ed by fluid boluses, titration/ discontinuation of  the infu-
sions and administration of  vasopressors17,18.  
It is established that remifentanil and dexmedetomidine 
cause hypotension at increasing therapeutic dose ranges. 
Standard doses which cause adequate anaesthesia/analge-
sia used are however lower than therapeutic doses and no 
studies have compared the proportion of  patients with 
hypotension between patients receiving the two drugs un-
der standard isoflurane anaesthesia in oxygen/air mixture 
at those rates of  infusion.  
Hypotension is a common side effect encountered during 
sedative/analgesic infusions administered as adjuncts of  
inhaled volatile and intravenous agents. Remifentanil in-
fusions have been associated with high incidences of  hy-
potensive episodes when compared to other opioids such 
as fentanyl21.  Dexmedetomidine has been shown to have 
a lower incidence of  hypotension when used peri-opera-
tively22.  
Our study question was does the use of  isoflurane anaes-
thesia plus dexmedetomidine infusion in adults undergo-
ing elective surgery result in fewer cases of  hypotension 
compared to isoflurane anaesthesia with remifentanil in-
fusion? We hypothesized that at maintenance doses of  
0.4 mcg/kg/hr of  dexmedetomidine and 0.2 mcg/kg/
min of  Remifentanil infusion there is no significant dif-
ference in the proportions of  patients with hypotension 
between the two groups.  
 
Our primary objective was to compare the proportion 
of  hypotension cases developing following isoflurane 
anaesthesia plus dexmedetomidine infusion to isoflurane 
anaesthesia plus remifentanil at standard doses in adult 
patients undergoing elective surgery.  Our secondary ob-
jectives were to compare the severity of  the lowest mean 
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arterial pressure recorded in hypotension among adult 
patients receiving dexmedetomidine infusion compared 
to those receiving remifentanil infusion, and to compare 
the number of  physician interventions in each group.  
Methodology 
The study was performed following approval from the 
ethical and scientific review Committee at the Aga Khan 
University, East Africa. The study was registered by the 
Pan African Clinical Trials Registry registration number 
PACTR201412000962379. It was a single blinded ran-
domized control trial. The target population included all 
adults aged between 18 and 85 years who underwent elec-
tive surgery at Aga Khan University Hospital, Nairobi. 
The sample population included 96 ASA I and II patients 
going to theatre for elective surgery between August 2014 
and March 2015. Reasons for exclusion from the study 
were:
1. Pregnancy 
2. Patients with severe liver and renal dysfunction  
3. Patients diagnosed to have mental disorders
4. Pre-existing bradycardia and brady-dysrhythmia  
5. Cardiovascular insufficiency and valvular heart 
    disease 
6. Hypotensive patients clinically diagnosed  
7. Patients who declined to participate in the research
A sample size of  96 patients (48 per group) was calculat-
ed to be sufficient to demonstrate 27% difference in the 
proportion of  hypotension between the remifentanil and 
dexmedetomidine group at a 95% confidence level and a 
power of  80%. A retrospective study looking at the hae-
modynamic impact of  dexmedetomidine administration 
in 15,656 non-cardiac surgical cases showed a proportion 
of  26.5% in hypotension and a meta-analysis of  20 stud-
ies demonstrated it at 26%19,20. Sneyd et al demonstrated 
a proportion in hypotension of  53% in patients under-
going major abdominal and gynecological surgery using 
remifentanil infusion at 0.2mcg/kg/min21.  
We therefore hypothesized that there would be no signifi-
cant difference in the proportion of  hypotension between 
the remifentanil group of  patients receiving a standard 
dose rate of  0.2 mcg/kg/min and the dexmedetomidine 
group receiving a standard dose rate of  0.4mcg/kg/hr.  
The study participants were recruited from the pre-op-
erative anaesthesia clinic (during the pre-anaesthetic re-
view) and the in-patient surgical ward. All participants 
received verbal and written explanation on the purpose 
and procedure of  the study from the principal investiga-
tor; and written informed consent. The patients who gave 
written informed consent were enrolled into the study 
and randomized. Their anaesthesia charts had indication 
of  study patient for ease of  identification on arrival in 
theatres. Simple randomization was done using a com-
puter program which generated a random sequence of  
numbers. Each of  the random numbers was sequentially 
assigned to either: Group D1; that would be on remifen-
tanil infusion intra-operatively or Group D2; that would 
be on dexmedetomidine infusion intra-operatively
The patient was blinded to the study. The primary anaes-
thesia team and the principal investigator were not blind-
ed due to near risk of  adverse event of  severe hypoten-
sion and bradycardia intra-operatively and the different 
preparation and administration of  remifentanil and dex-
medetomidine infusions. Dexmedetomidine was recently 
introduced into the Kenyan market and the anaesthesia 
team had limited experience with the drug. We sourced 
this drug for our study from our hospital pharmacy where 
it had been recently added to the hospital formulary.  The 
recruitment process and patient distribution is illustrated 
in figure 1.
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This study was undertaken at the Aga Khan University 
Hospital, Nairobi operating theaters.  
ASA I or II patients scheduled for elective surgical pro-
cedures were received in the pre-operative area. They had 
been randomized to receive remifentanil 0.2mcg/kg/
minute or dexmedetomidine at 0.4mcg/kg/hour after 
induction as an adjunct to isoflurane maintenance anaes-
thesia.  The anaesthesia team conducting the anaesthe-
sia received the anaesthetic chart with the attached data 
collection tool.  The team included the consultant anaes-
thetist and the resident. The study drug was prepared by 
the anaesthesia residents who were not involved in the 
randomization process.  
Remifentanil Ultiva® 2mg was diluted to 40mls with wa-
ter for injection to constitute 50mcg/ml and attached to 
an infusion pump. Dexmedetomidine Dexem® was dilut-
ed to 50mls with water for injection to constitute 4mcg/
ml and attached to an infusion pump.  
 
The infusion pumps used for the study were Injectomat 
TIVA Agilia anaesthesia syringe pump by Fresenius 
Kabi®. Once received into the operating rooms, the pa-
tient had standard monitoring equipment attached. These 
were temperature, non-invasive blood pressure, electro-
cardiography and pulse oximetry. The baseline cardiovas-
cular and respiratory parameters were established- blood 
pressure, heart rate, respiratory rate and oxygen satura-
tion.The baseline average mean arterial pressure was de-
termined using mean arterial pressures on anaesthesia re-
view, prior to entry into theater (in the wards) and prior 
to induction.  
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Figure 1: Flow diagram of patient distribution    
PATIENTS RECRUITED (104) 
OBTAINED CONSENT (104) 
EXCLUDED (0) 
RANDOMIZED (104) 
GROUP D1 RECEIVED 
REMIFENTANIL AT 
0.2MCG/KG/MIN (53) 
GROUP D2 RECEIVED 
DEXMEDETOMIDINE INFUSION 
AT 0.4MCH/KG/HR (51) 
DATA ANALYSED 
(104) 
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Intravenous cannulation was achieved with standard B. 
Braun Venflow® cannula of  Gauge 18.  Hartmann’s solu-
tion was run fully at 15 mls/kg as induction was initiated. 
No premedication was administered.   The patient was 
then pre-oxygenated for three minutes.  The patients ran-
domized to D1 received remifentanil at a loading dose 
of  1mcg/kg for 60 seconds and received propofol at 1.5 
mg/kg thereafter.  
   
The patients randomized to D2 received dexmedetomi-
dine at a loading dose of  1mcg/kg for 10 minutes with 
propofol administered in the 7th minute at 1.5mg/kg. 
Isoflurane was initiated after induction. Patients in both 
groups received Cisatracurium Nimbex® at 0.15-0.2mg/
kg to facilitate endotracheal intubation and muscle paral-
ysis.  
 
Maintenance of  Isoflurane was targeted at end tidals of  
0.8- 1.2% in an oxygen and air mixture at low flow anaes-
thesia. The infusion rates were targeted at the minimum 
dose rates in both groups (0.05mcg/kg/min in remifen-
tanil and 0.2mcg/kg/hr in dexmedetomidine) after in-
duction prior to the first surgical stimulation. This was 
to avoid unnecessary episodes of  hypotension prior to 
surgery.  
Group D1 receiving remifentanil infusion had the main-
tenance rate initiated at 0.2mcg/kg/minute and 0.4mcg/
kg/hour for the patients in Group D2 receiving dexme-
detomidine infusion at the start of  surgical stimulation. 
Intra-operative intravenous fluid maintenance require-
ments were calculated using the Holiday- Segar regimen 
with Hartmann’s solution. All patients received antiemet-
ic medication of  the anaesthetist choice and when indi-
cated.  Blood pressures were recorded as per standard 
protocol after induction every five minutes up to the end 
of  anaesthesia.  
 
Hypotension was defined as a 30% reduction in the base-
line mean arterial pressures. The hypotensive episodes 
occurring during surgery were noted and recorded on the 
data collection tool in each group. A fluid bolus of  Hart-
mann’s solution at 10mls/kg was given to treat the first 
episode of  hypotension. Subsequent episodes of  hypo-
tension were managed by administration of  vasopressor 
boluses and fluid boluses at the anesthetist's discretion. 
The vasopressors used were either boluses of  phenyleph-
rine at 50mcg/ml or ephedrine at 3mg/ml. When hypo-
tension persisted for more than twenty minutes despite 
physician intervention, the dose was titrated downwards 
at decrements of  0.05 in remifentanil and 0.1 in the dex-
medetomidine infusions. The infusion rate was recorded 
every 15 minutes.   
   
When hypotension persisted despite vasopressor, flu-
id support and infusion titration to the minimum dose 
rate required, the infusions were discontinued and noted. 
Once mean arterial pressures returned to the baseline, 
the infusions were recommenced and titrated according-
ly with the aim of  resuming the standard rates of  infu-
sion or maintaining at rates well within the recommended 
prescriptions that did not yield hypotensive episodes and 
maintained anaesthesia/analgesia.  In the event of  hy-
pertension i.e. MAPS that were a 30% increase from the 
baseline, the rates of  both infusions were increased grad-
ually in increments of  0.1 for dexmedetomidine and 0.05 
in remifentanil. The maximum therapeutic rate for dex-
medetomidine was 0.7mcg/kg/hr. and  0.5mcg/kg/min 
for remifentanil. Intraoperative bradycardia was treated 
with 300mcg of  atropine intravenously.
 
Multimodal analgesia was administered as indicated. These 
included Paracetamol, non-steroidal anti-inflammatory 
drug (NSAID) when indicated intra-operatively and an 
opioid of  the anesthetist’s preferred choice intra-opera-
tively as a sub-cutaneous injection half  an hour to the 
end of  the surgical procedure in the remifentanil group to 
avoid remifentanil-induced hyperalgesia post-operatively 
and upon reversal for the dexmedetomidine group to 
avoid increased sedation post-operatively. Dexmedetomi-
dine was discontinued fifteen minutes before the end of  
surgery. Remifentanil, air and isoflurane were terminated 
five minutes to the end of  surgery or on the last stitch. 
Reversal was conducted on appropriate oxygen flows. At-
ropine was given at 20mcg/kg, glycopyrrolate at 200mcg 
for each 1mg of  neostigmine which was given at 50mcg/
kg. Patients were reversed from anaesthesia and trans-
ferred to the post-anaesthesia care unit (PACU).                
Intra-operative data was collected by the anaesthesia team 
using the data collection form.  
At PACU, the form was verified by the principal inves-
tigator to ensure it was filled correctly post-operatively. 
The collected data material was placed in an envelope and 
stored in a lockable filing drawer in the supervisor’s of-
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fice. All the sheets were checked once again to confirm 
completeness before being filed. The processed data was 
manually entered and saved in an external portable drive 
(USB) and copies were kept in the supervisor’s office. The 
collected data were then manually entered by the princi-
pal investigator into an MS-Excel data base for analysis.  
   
Data collected was analyzed using SPSS software version 
20 by IBM. It was presented in the form of  tables and 
graphs.  Mean values with standard deviations were used 
to describe the patients age, weight and baseline pressures 
i.e. MAPS, systolic and diastolic pressures, lowest MAP 
throughout surgery and volume of  Hartmann’s fluid 
boluses. Unpaired Student T- test was used to compare 
means between the two groups. Gender, ASA status, op-
erative procedures and variables such as the use of  vaso-
pressors, titrated rate of  infusion cessation of  infusion 
were represented as proportions and compared using the 
Pearson’s chi square test or Fischer’s exact test.    
The proportion of  hypotensive cases developing in iso-
flurane anaesthesia plus dexmedetomidine infusion and 
in remifentanil respectively were presented and compared 
using Fischer’s exact test.  The relative risk ratio was also 
calculated between the two groups and with confidence 
intervals. The tests were calculated under the assumption 
of  equal variance. P-values ≤0.05 were considered statis-
tically significant. The collected data was kept private and 
confidential at all times.  
Results  
One hundred and four ASA I and II patients scheduled 
to undergo elective surgery were recruited to this study. 
There was no loss to follow-up of  patients during recruit-
ment and pre-operatively. The patient demographics and 
baseline characteristics are illustrated in table 1.  
Student t-test was used to compare age and between the 
two groups, whereas Pearson’s chi square test was used 
to compare the gender and ASA status. There was no 
statistical difference in the patient’s weight and ASA sta-
tus between the groups. However significant p values 
were generated from the age and gender. These statistical 
significances could influence the outcome of  the study 
despite it being a result of  chance from the process of  
randomization and clinically may be of  value.    
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Table 1: Patient characteristics   
 
   Overall    
N=104    
Remifentanil   
Group n=53    
Dexmedetomidine 
Group n=51    
P- value 
Age in Years   
36±12.00   
(18-75)   
36.37±10.34   
(18-70)   
41.72±13.00   
(19-75)   
0.023   
Sex                                                          
Male   50(48.08%)   31(58.48%)   19(37.25%)   0.05   
Female   54(51.92%)   22(41.52%)   32(62.75%)   
Weight in KG   
75.16±17.59  
(41.5-154)   
 72.38±11.32   
(52-103)   
78.04±22.07   
(41.5-154)   
  
0.1188 
ASA STATUS                              
I   61(58.65%)    32(57.4%)   29(56.86%)    0.8692 
II   43(41.35%)   21(42.6%)   21(43.14%)   
    ASA- American Society of Anaesthesiologists. NS- Not Statistically significant mean, standard   
    deviation, minimum and maximum ranges in brackets are given for Age and weight. Proportions  
    are demonstrated in the ASA status.  
More than 50% of  the elective procedures were from 
general surgery and orthopedics. Although the types of  
surgeries conducted was not analyzed, their nature could 
have influenced the proportion of  hypotension between 
the groups. This is illustrated in table 2.  
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Table 2: Operative procedures   
 
   
Overall    
N=104    
Remifentanil   
Group n=53    
Dexmedetomidine   
Group n¹=51    
P value 
General   
Surgery   
34(32.69%)  10(18.9%)   24(47.1%)   0.084 
Gynaecology   24(23.08%)  16(30.2%)   8(15.7%)   
Maxillofacial 
surgery   
6(5.77%)   3(5.7%)   3(5.9%   
Neurosurgery   5(4.81%)   3(5.7%)   2(3.9%)   
Orthopedic 
surgery   
26(25.00%)  14(26.4%)   12(23.5%)   
Plastic 
Surgery   2(1.92%)   2(3.8%)   0(0.0%)   
Ear Nose 
and   
Throat 
Surgery  
5(4.81%)   4(7.5%)   1(2%)   
Urology 
surgery 
2(1.92%)   1(1.89%)   1(1.96%)   
   
  Fisher’s exact test was used to compare the distribution of surgical procedures between  
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 The duration of  surgery was greater in the patients receiv-
ing remifentanil infusion compared those receiving dex-
medetomidine infusion and was statistically significant as 
illustrated in table 3. This was a result of  the recruitment 
process. The baseline pressures prior to commencing sur-
gery between the two groups were similar.
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Table 3: Duration of surgery    
 
   Overall    
N=104    
Remifentanil il Group 
n=53    
Dexmedetomidine   
Group n¹=51    
P value    
Duration of 
Surgery in 
minutes   
101.54±51.35  121.75±54.  
45   
80.54±38.27   <0.0005  
BASELINE   
MAPS   
(mmHg)    
88.89±12.94   
(60-120)   
72.38±11.3  
3 (65-120)   
78.04±22.08   
 (60-114)   
0.1011  
BASELINE   
SYSTOLIC   
PRESSURE   
(mmHg)   
119.40±15.78 
(100-145)   
 119.00±11.  
64 (100-  
144)   
121.68±11.53       
(100-145)   
0.2279  
BASELINE   
DIASTOLIC   
PRESSURES   
(mmHg)   
74.13±10.10   
(50-101)   
73.77±11.1  
0 (50-101)   
74.51±9.04 (54-95)  0.7107  
MmHg- millimeters of Mercury, minimum and maximum values are in brackets.   
The means of the pressures between the two groups was compared with unpaired t-test.   
The use of  NSAIDs when compared between the two 
groups did not yield any statistical significance. Parac-
etamol was used in all recruited patients. Morphine was 
the most common opioid analgesic preferred by the an-
aesthesia team. There was greater administration of  mor-
phine in patient’s receiving remifentanil. This was based 
on the preference of  the anaesthesia team and was statis-
tically significant.  This is illustrated in table 4.
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Table 4: Analgesia administered in the operating room    
 
ANALGESIA                                                                                      
   Overall    
N=104    
Remifentanil   
Group n=53    
Dexmedetomidine 
Group n¹=51    
P value   
Paracetamol   104(100%)   53(100%)   51(100%)   1    
NSAIDs   89(85.58%)   44(83%)   45(88.2%)   0.449   
NSAIDs 
Avoided 15(14.42%) 9(17%) 6(9.8%)   
OPIOID USE   
Morphine   90(86.54%)   51(96.22%)   39(76.47%)   0.2365      
Pethidine   3(2.88%)   1(1.89%)   2(3.92%)   
Tramadol   4(3.85%)   0(0.00%)   4(7.84%)   
None   7(6.73%)   1(1.89%)   6(11.6%)   
  
Pearson’s uncorrected Chi square test was used to compare the use of analgesia between  
the two groups.  
The proportion of  hypotension episodes developing be-
tween patients receiving dexmedetomidine infusion and 
remifentanil infusion is illustrated in the figure 2 and table 
5.  
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Figure 2 showing the proportion of patients who developed 




P value using Fischer’s exact test <0.001 
Table 5: Relative risk ratio for having at least one hypotensive episode    
 
   Hypotension    
Normal    
Blood    
Pressure    
TOTAL    
Dexmedetomidine  
infusion   
24(47.06%)   27(52.94%)   51   
Remifentanil infusion  42(79.25%)   11(20.75%)   53   
R.R= 0.5938             
95%     
C.I= 0.329-0.819    
   
      
 R.R- Relative Risk ratio, C.I-Confidence interval 
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There was a greater proportion of  hypotension in pa-
tient’s receiving remifentanil versus patients receiving 
dexmedetomidine (79.25% against 47.06 %) at standard 
rates of  0.2mcg/kg/minute versus 0.4mcg/kg/hour.  
The proportion of  patients with a hypotensive episode 
between each group was statistically significant (p val-
ue <0.0001).    The risk ratio being less than 1 implied 
the likelihood of  hypotension developing in patients re-
ceiving remifentanil infusion at 0.2mcg/kg/minute was 
59.38%.      
There were more episodes of  hypotension in the remifen-
tanil arm (3.04 per patient) than in the Dexmedetomidine 
arm (2.08 per patient) as illustrated in table 6.
 
Table 6: Number of hypotensive episodes in patients 
with hypotension during surgery 
   
   EPISODES OF 
HYPOTENSION   
Remifentanil n=42    128   
Dexmedetomidine n¹= 24    
50   
  
 
Comparison of  the lowest hypotensive MAP was done 
using independent student t test.  
The lowest hypotensive mean arterial pressures between 
the two groups recorded were similar and not statistically 
significant as shown in table 7. This is clinically satisfac-
tory.  
Table 7: The lowest hypotensive MAP recorded during surgery 
 
              
              Overall    
N=66    
Remifentanil 
Group n=42   
 Dexmedetomidine   
 Group n¹=24      
 P- value    




mmHg   
53.81±7.48   53.34±7.22   54.63±7.98   0.5040  
   MmHg- Millimeters of mercury  
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The management required variable physician interven-
tions which included: -  
1. Administration of  Hartmann’s solution boluses.
2. The administration of  vasopressors.
3. Titration of  infusions.
4. Termination of  the infusions.
These were options left to the discretion of  the team. 
They were used as single or combined treatments. Forty 
five patients from both arms received Hartmann’s fluid 
bolus. 65.96% of  the patients who experienced hypoten-
sion were in the remifentanil arm against 48.15% in the 
Dexmedetomidine arm. Volumes received in both arms 
of  the study is illustrated in table 8. 
Table 8: Volume of Hartmann’s fluid boluses administered to treat  
the patients with hypotension 
 
   Overall N=45   
 Remifentanil   
Group n=31    
Dexmedetomidine 
Group n¹=14    




given  in mls   
181.81±106.25 
(100-500)   
  
 187.1±111.78  
(100-500)   
 169.23±94.73   
(100-400)   
0.6064  
 
       The means of the volume of Hartmann’s fluid bolus of the two groups were compared with    
       unpaired t-test.   
The mean volume infused in the dexmedetomidine group-
was less compared to the remifentanil arm but there was 
no statistical significance. 19.70% of  the patients who 
developed hypotension received ephedrine and 28.78% 
received phenylephrine. The use of  ephedrine between 
the groups was significant as illustrated in table 9. Fish-
er’s exact test was used to compare the two groups.  The 
proportion of  patients requiring the infusion rates to be 
titrated downwards was similar between the two groups 
at 79.17 % in the dexmedetomidine group and 85.71% in 
the remifentanil group.   The minimum rate of  infusion 
in each group remained in the recommended dose ranges 
suitable for anaesthesia in patient’s undergoing surgery. 
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Table 9: Use of vasopressors in patients with hypotension during surgery 
 
   Overall    
N=66    
Remifentanil l 
Group n=42 
Dexmedetomidine   
Group n¹= 24    
 P value    
Ephedrine    13(19.7  4 (9.52 %)   9(37.5 %)   0.036062  
   
Overall   
N=66    
 Remifentanil 
Group n=42   
 Dexmedetomidine    
 Group n¹= 24    
P-value   
Phenylephrine   
 19  (28.78%)   
13(30.10 %)   
  
6(25.00 %)   0.0 
 
The proportion of  patients requiring termination of  the 
infusion was higher in the remifentanil arm at 11.90 % 
while the dexmedetomidine group had none.  This was 
statistically insignificant following comparison of  the two 
study arms with Fischer’s exact test p= 0.1499. The av-
erage rate of  infusion of  remifentanil and dexmedetomi-
dine in the patients recruited in this study was 0.154mcg/
kg/minute (S.D±0.05) and 0.39mcg/kg/hour (S.D±0.13) 
respectively.   
Discussion  
Intra-operative hypotension remains a common side ef-
fect of  inhaled and intravenous anaesthetics agents used 
in general anaesthesia.  This study demonstrated that 
there was a significantly higher proportion of  patients re-
ceiving remifentanil infusion who developed hypotension 
than those on dexmedetomidine. Among patients in ei-
ther group who developed hypotension, the hypotensive 
episodes were also more frequent in the patients receiving 
remifentanil infusion.  
Salman and his colleagues compared remifentanil to 
dexmedetomidine at similar infusion rates in females 
undergoing ambulatory laparoscopic gynecological pro-
cedures23. The loading dose during induction was ten 
minutes in each group whereas in this study, remifentanil 
was loaded for one minute as prescribed.  
Their baseline characteristics including duration of  sur-
geries were similar between the two groups. The popula-
tion in this study had both gender and heterogeneous op-
erative procedures. They used BIS monitoring to ensure 
standardized depth of  anaesthesia which was not used 
here. They noted the systolic blood pressures between 
the two groups were similar and did not report hypoten-
sion throughout surgery. The results in the current study 
have shown that hypotension does occur at these rates of  
infusion and is frequent 2.7 vs 2.1 per patient in remifen-
tanil and dexmedetomidine respectively.   The current 
study demonstrated that despite the occurrence of  hypo-
tension, the lowest mean arterial pressure readings during 
surgery between the two groups was clinically acceptable. 
No adverse cardiovascular events were reported requiring 
resuscitation which is similar to Salman’s findings.  
  
Jung et al compared the haemodynamic profile of  remifen-
tanil and dexmedetomidine infusions at varying infusion 
protocols and the blood pressures were significantly low-
er in patients on dexmedetomidine24. This is different 
from the current results. Although infusion rates were 
well within the recommended doses, their infusion rates 
were as high as 0.7 mcg/kg/hour, which is higher than 
the 0.4mcg/kg/hour used in the current study. Thus, it is 
possible that the higher rates of  hypotension were due to 
their higher infusion rates. The lowest mean arterial pres-
sure during surgery was similar between the two groups 
revealing the safety profile of  both drugs during surgery 
and there were no cardiac adverse events and significant 
blood loss reported.  
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The females enrolled in the study were slightly greater 
than males and did not influence the outcome of  propor-
tion of  patients with hypotension between the groups. 
This was a result of  the recruitment process. The propor-
tion of  patients with hypotension between the sexes was 
not significant (p = 0.8023). Women physiologically have 
an active parasympathetic system, higher estrogen levels 
and a lower center of  gravity which would influence blood 
pressure as demonstrated by Cheng and his colleagues25 
but Sachin Kheterpal et al demonstrated that gender was 
not a predictor of  cardiac adverse events peri-operatively 
in patients undergoing elective surgery26.  
  
The average infusion rate of  dexmedetomidine was 
0.39mcg/kg/hour indicating better hemodynamic stabili-
ty in the population selected for the study. The average in-
fusion rate of  0.154mcg/kg/min in remifentanil showed 
this could be the rate of  infusion that provides haemody-
namic stability in our population as opposed to 0.2mcg/
kg/min in this study.
The volume of  Hartmann’s solution administered as bo-
luses was similar between the two groups. There was a 
greater preference in using phenylephrine than ephedrine 
in both arms. Using weight based infusions and calculat-
ing the percentage increase from the mean arterial pres-
sure could have been a better measure of  the value of  
volume boluses and managing hypotension.  Ephedrine 
was commonly used to raise blood mean arterial pres-
sures in the dexmedetomidine arm (37.5% vs 8.51%; p 
= 0.007). The mode of  managing hypotension was at the 
discretion of  the anaesthetist. Comparing a single agent 
for example phenylephrine at 100mcg and determining 
the time period before the next hypotensive episode may 
have demonstrated the value of  the vasopressors in man-
aging episode between the two arms. 
  
No study has determined the equipotent doses of  
remifentanil and dexmedetomidine. It would be very 
valuable but costly as laboratory tests are necessary for 
each patient. This would then enable us to induct studies 
in the same setting to yield better and accurate results.  
This study has demonstrated the average rate of  infu-
sions required in remifentanil and dexmedetomidine in 
the Kenyan population undergoing surgery. It has also 
raised awareness on dexmedetomidine as an adjuvant to 
inhaled anaesthetic agents and its use peri-operatively.  
The use of  dexmedetomidine intra-operatively as a sub-
stitute to remifentanil infusion would result in a lower 
proportion of  patients getting hypotension and fewer ep-
isodes during surgery. Other studies have shown it also 
reduces the risk of  apnoea, nausea, vomiting and opioid 
induced hyperalgesia during recovery. The effect of  low-
er sedation scores may be suitable in patients requiring 
sedation post-operatively. Termination of  its infusion is 
very important in patients requiring prompt ambulation 
for example day care surgery  
  
Limitations
Limitations to the study include the use of  simple ran-
domized sampling. We did not use Bispectral index (BIS) 
monitoring to ensure standard depth of  anaesthesia and 
eliminate the probability of  the inhaled anaesthetic agent 
contributing to the hypotension in patients. BIS monitor-
ing is available at our hospital but is very costly. It would 
be unethical to extend the cost to the patient and the bud-
get allocated for the study was short of  covering the cost. 
Lastly our study had single blinding and this could have 
been a potential source of  bias.    
 
Conclusion   
The conclusion to this study is that at standard infusion 
rates, the proportion of  patients and risk hypotension is 
greater in patients undergoing elective surgery receiving 
remifentanil at 0.2mcg/kg/min than in dexmedetomidine 
at 0.4mcg/kg/hr. under isoflurane anaesthesia.
Conflit of  interest
None.
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